The Food and Drug Administration Friday reissued its emergency use authorization for the LabCorp COVID-19 RT-PCR Test to include authorized use for asymptomatic individuals and for pooled sample testing with up to five individual specimens. FDA previously authorized emergency use of the test for patients with suspected COVID-19 and individual specimens.

“FDA’s authorization of the first diagnostic test to be used for anyone, regardless of whether they are showing symptoms of COVID-19 or have other exposure risk factors, is a step toward the type of broad screening that may help enable the reopening of schools and workplaces,” said FDA Commissioner Stephen Hahn, M.D. “By authorizing another test for use with pooled samples, we also further help increase the possibility that patients may be able to receive results sooner, while also conserving vital testing supplies, which are under increased demand during the pandemic.”

Related News Articles

Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…
Headline
The Federal Emergency Management Agency this week released recommendations to help organizations receiving FEMA COVID-19 public assistance document and…
Headline
The Food and Drug Administration today urged health care facilities to transition away from using crisis capacity conservation strategies, such as…
Perspective
When Congress returns to Washington, D.C., on Monday, lawmakers’ attention will turn to one of the largest infrastructure spending packages in our nation’s…
Headline
The COVID-19 pandemic has shown how crucial technology is for health care delivery, but individuals without broadband access cannot access digital health…
Headline
Nearly 80% of prekindergarten through 12th grade teachers, school staff and child care workers had received at least their first COVID-19 shot by April, the…